Immuron Limited announced its CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on May 7, 2026, highlighting its platform technology and pipeline products including Travelan®, IMM-529 for recurrent Clostridioides difficile infection, and ProIBS® for IBS under an exclusive distribution agreement in Australia and New Zealand.
Key takeaways
CEO Steven Lydeamore to present at the Emerging Growth Conference on May 7, 2026 — signals continued investor engagement and corporate visibility.
Travelan® (IMM-124E) is a tabletized oral passive immunotherapy targeting ETEC-induced travelers’ diarrhea, approved as a listed medicine in Australia and natural health product in Canada, and sold as a dietary supplement in the U.S.
IMM-529, in development for recurrent Clostridioides difficile infection, targets Toxin B, spores, and surface layer proteins — demonstrated 67% protection against recurrence (p<0.01) in pre-clinical models.
Immuron has an exclusive distribution agreement with Calmino group AB for ProIBS® in Australia and New Zealand — a certified medical device for IBS symptoms containing AVH200® derived from Aloe barbadensis.